Avricore Health Inc. Files April 2025 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: May 20, 2025 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing, company-update
Related Tickers: AVRX
TL;DR
Avricore Health (AVRX) filed its April 6-K report, standard foreign issuer update.
AI Summary
Avricore Health Inc. filed a Form 6-K on May 20, 2025, for the month of April 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is headquartered at 1120-789 West Pender St, Vancouver, BC, V6C 1H2. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides an update on Avricore Health Inc.'s activities and regulatory disclosures for April 2025, which is important for investors tracking the company's ongoing operations and compliance.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Numbers
- 20250520 — Filing Date (Indicates the date the report was submitted to the SEC.)
- 20250430 — Reporting Period End Date (Specifies the end date of the period covered by the report.)
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
- 000-51848 (dollar_amount) — Commission File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country or its charter or by-laws.
What is Avricore Health Inc.'s primary business classification?
Avricore Health Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
When did Avricore Health Inc. change its name from Vanc Pharmaceuticals Inc.?
The company changed its name from Vanc Pharmaceuticals Inc. on 20140911.
What is the principal executive office address for Avricore Health Inc.?
The principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Is Avricore Health Inc. submitting this Form 6-K in paper format?
No, the filing indicates that the registrant is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 20, 2025 regarding Avricore Health Inc. (AVCRF).